Maxion doubles R & D space at Unity Campus after £58m Series A

Following its £58 million Series A funding round earlier this year, Maxion has signed a new lease for Suite 5 at The Works building, securing nearly 9,000 sq ft of additional transformative laboratory and office space at Unity Campus to support the next stage of its growth journey. The expansion takes Maxion’s total space at Unity Campus to over 16,000 sq ft.

The new space will enable Maxion, which first moved to Unity Campus in 2023, to continue scaling its research and development activities from a single, cohesive location, as it works towards its ultimate goal of improving the quality of life of patients with debilitating diseases.

Howard Group worked closely with Maxion to create a tailored real estate solution, aligning the new lease for Suite 5 with Maxion’s existing lease on Suite 4 (7,644 sq ft). This synchronisation offers important operational benefits and avoids unnecessary disruption to Maxion’s R&D work at Unity Campus.

Founded in 2019, Maxion Therapeutics leverages its revolutionary KnotBody® technology to develop antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.

Its recent landmark fundraising – one of the largest European private biotech financings since the beginning of 2024 – highlights the significant potential of the technology and development pipeline.

CEO Arndt Schottelius said: “This new space helps expand our translational biology as well as research and development capabilities and comes at an exciting time for Maxion following our recent Series A fundraising.

“It will play an important role in progressing our lead KnotBody programme, MAX001, in preclinical development to target a broad spectrum of inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.”